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Abstract
Introduction: Nephrogenic adenomas are generally considered to be benign lesions, but there
remains a risk for malignant transformation. Patients with immunosuppression in particular appear
to be at a higher risk of malignant disease. We report a case of post-traumatic nephrogenic
adenoma in a young patient without immunosuppression, which transformed into an
adenocarcinoma of the bladder.
Case presentation: A 25-year-old man had a traumatic bladder perforation caused by a car
accident. After physical recovery from the accident, he developed a neurogenic bladder and
recurrent urinary tract infections. He presented with nephrogenic adenoma of the bladder 18
months after the accident. The adenoma was treated repeatedly with transurethral resections. The
initial pathologic findings were benign, however, the last resection revealed that the former benign
adenoma had transformed into a moderately differentiated adenocarcinoma of the bladder (tumor
present but no invasion, multifocal, no lymph nodes involved, no metastasis, grade 2). He
subsequently underwent radical cystectomy and has remained tumor-free for the last 4 years.
Conclusion:  Nephrogenic adenoma is a rare disease with some potential for malignant
transformation. However, patients with nephrogenic adenoma under immunosuppression and
patients with neurogenic bladder dysfunction appear to be at a higher risk of developing bladder
cancer.
Introduction
Nephrogenic adenoma is a rare tumor which usually
occurs in the urinary tract, most frequently in the bladder.
Its etiology is unknown, but association with trauma,
nephrolithiasis, urinary tract infection and radiation has
been reported [1]. Diagnosis is based on histopathologic
examination. The therapy of choice in small tumors is
transurethral resection, however, a high recurrence rate of
37% to 88% has been reported [2]. Occasionally, these
rare tumors are associated with urothelial neoplasms, ade-
nocarcinoma or squamous cell carcinoma of the bladder
[2-4].
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Case presentation
A 25-year-old man had a car accident with severe head
injury, pelvic fractures, rupture of the symphysis, partial
urethral rupture and traumatic bladder perforation at the
bladder dome with extension to the right bladder wall.
The bladder perforation was treated with primary bladder
closure, while the partial urethral rupture was treated with
urethral catheterization. The patient's overall health status
improved progressively, however, he developed neuro-
genic bladder dysfunction. Thus, a suprapubic catheter for
continuous bladder drainage was necessary for 1 year.
One and a half years after suprapubic catheter removal, he
presented with sterile microhematuria confirmed by
repeated urine examinations. Cystoscopy detected a pap-
illary tumor at the right and posterior bladder wall with
extension to the bladder base. The bladder dome was
tumor-free. The tumor was removed by transurethral
resection (TUR). The histologic diagnosis of nephrogenic
adenoma was confirmed by two independent patholo-
gists.
Follow-up consisted of routine urine analysis, cystoscopy
and cytology every 3 months. A second TUR was per-
formed because of histologically proven recurrence. The
upper urinary tract never showed any signs of tumor
spread. Microhematuria occurred again 1 year after initial
presentation of the tumor. Cystoscopy now found a dif-
fuse and progressive growing exophytic tumor with exten-
sion almost throughout the entire bladder wall (Figure 1).
Cytology revealed malignant cells suspicious for adeno-
carcinoma. Further histologic examination confirmed the
reappearance of the nephrogenic adenoma (Figure 2).
However, additional focal transformation to a moderately
differentiated adenocarcinoma was detected (Figure 3).
Staging procedures were negative for metastatic spread. A
primary tumor origin in the gastrointestinal system was
excluded. A radical cystoprostatectomy with neobladder
reconstruction was performed because of the diffuse and
extensive growth pattern. Final histology confirmed neph-
rogenic adenoma with multifocal transformation to a
moderately differentiated adenocarcinoma with tubular
growth pattern. Postoperative tumor classification was
tumor present but no invasion (pT1), multifocal, no
lymph nodes involved (pN0), no metastasis M0, grade 2
(G2) and resection shows no tumor (R0). The current fol-
low-up is 4 years and the patient remains tumor-free.
Discussion
Nephrogenic adenoma was described in 1949 as hamar-
toma of the bladder [5]; the term nephrogenic adenoma
was introduced by Friedman and Kuhlenbeck [6]. Cur-
rently this disease is assumed to be a metaplastic process,
thus terms such as nephrogenic metaplasia or adenoma-
toid metaplasia have been established.
Nephrogenic adenoma is a rare tumor, which usually
occurs in the urinary tract, most frequently in the bladder.
Its etiology is unknown, but association with trauma,
nephrolithiasis, infection and radiation has been reported
[1]. Most patients are adults with an increased incidence
in renal transplant patients [7,8]. In these patients, the
renal origin was detected by genetic analysis [9]. About
Histology of a nephrogenic adenoma Figure 2
Histology of a nephrogenic adenoma. Papillary and 
tubular growth pattern of nephrogenic adenoma is shown, 
partly with small cysts with eosinophilic material. This histo-
logical picture was found throughout the entire urothelium 
of the cystectomy specimens (approximately 50% of the 
urothelial surface of the bladder). Hematoxylin and eosin 
stain, magnification ×100.
A computed tomography scan showing a thickening of the  entire bladder wall with no predominant location, such as the  bladder dome Figure 1
A computed tomography scan showing a thickening 
of the entire bladder wall with no predominant loca-
tion, such as the bladder dome.Journal of Medical Case Reports 2008, 2:164 http://www.jmedicalcasereports.com/content/2/1/164
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55% occur in a papillary growth pattern, 35% are sessile
and 10% are polypoid. Although most nephrogenic ade-
nomas are small, 10% are larger than 4 cm in diameter
[1]. Diagnosis is based on histopathologic examination.
The therapy of choice in small tumors is transurethral
resection, however, a high recurrence rate of 37% to 88%
has been reported [2].
Although nephrogenic adenomas are considered to be
benign lesions [5,6], malignant transformations have
been reported suggesting a premalignant disease [10], par-
ticularly in immunocompromised patients. The malig-
nant entity of nephrogenic adenoma is supposed to be the
so-called mesonephroid adenocarcinoma of the bladder
[11], but an association to transitional cell carcinoma has
also been reported [12]. The first mesonephroid adeno-
carcinoma was reported in 1968 by Dow and Young [13],
but only 15 cases with mesonephroid adenocarcinoma
have been published so far. Histologically, a tubular
growth pattern is pathognomonic for the mesonephroid
adenocarcinoma [14]. The current case of an adenocarci-
noma with tubular growth pattern supports the hypothe-
sis of transformation to a mesonephroid
adenocarcinoma. A study by Hartmann et al. [15] evalu-
ated molecular genetic hybridization in a similar case and
suggested clonal evolution of nephrogenic adenoma to
clear cell adenocarcinoma. This result supports the
hypothesis in the present case. However, the value of DNA
profiling is unclear because the detection of tumor entities
with low malignant potential, as in the present case,
seems to be limited [16].
A recently described entity that may be similar histologi-
cally to adenocarcinoma is a fibromyxoid nephrogenic
adenoma [17]. The present case is different and cannot be
interpreted as fibromyxoid nephrogenic adenoma
because there were no fibromyxoid areas in the tumor and
also no spindle cell component.
Patients with neurogenic bladder dysfunction, and espe-
cially those with continuous urethral or suprapubic cath-
eter drainage, are known to be at an increased risk of
developing bladder tumors. The incidence increases 10
years after the initial catheter placement [18]. The tran-
sient suprapubic catheterization in the current patient
might have played a role in the development of the
present nephrogenic adenoma or adenocarcinoma. This is
unlikely, however, since the catheter was only in place for
18 months. In addition, the most common type of blad-
der cancer in these patients is squamous cell carcinoma
rather than adenocarcinoma.
Furthermore the primary tumor was at the right and pos-
terior bladder wall and not at the bladder dome, the
former cystostomy site. All these findings do not support
the catheter as a primary cause for tumor development.
However, etiological relevance of chronic catheter irrita-
tion in the development of the malignant transformation
cannot be ruled out.
It is reported that adenocarcinomas have their origin from
the urachus. These tumors usually arise from the bladder
dome, the insertion point of the urachus. The location of
the primary tumor, however, does not support the
hypothesis in this case. The adenocarcinoma rather
occurred multifocally within the nephrogenic adenoma.
Conclusion
Nephrogenic adenoma is a rare benign disease with some
potential for malignant transformation. In particular, in
patients under immunosuppression and patients with
neurogenic bladder dysfunction, the risk of development
of bladder cancer might be increased and should be kept
in mind in the surveillance of patients with nephrogenic
adenoma.
Competing interests
The authors declare that they have no competing interests.
Histology of a nephrogenic adenoma with focal development  of an invasive adenocarcinoma Figure 3
Histology of a nephrogenic adenoma with focal 
development of an invasive adenocarcinoma. Invasive 
mesonephroid adenocarcinoma of the bladder adjacent to 
the nephrogenic adenoma is indicated by the arrow. In the 
right upper quadrant of the histological picture, the focal 
transformation to mesonephroid adenocarcinoma is shown. 
Hematoxylin and eosin stain, magnification ×400.Publish with BioMed Central    and   every 
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